Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leptin may indicate breast cancer risk:

This article was originally published in Clinica

Executive Summary

Measuring blood levels of leptin in women may provide an further indicator of their risk of developing breast cancer, say researchers at The University of Texas MD Anderson Cancer Center. Because increased fat is associated with increased bioavailable oestrogen and breast cancer risk, "measuring leptin could be an additional marker for assessing breast cancer risk," says investigator, Dr Richard Hajek.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel